Erratum: Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation (Cell Metabolism (2017) 26 (394–406.e6) (S1550413117304308) (10.1016/j.cmet.2017.07.009));Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation

Cell Metabolism

Volumn 26, Issue 2, 2017, Pages 394-406.e6

  Kim, Chai Wan ^a   Addy, Carol ^b   Kusunoki, Jun ^b   Anderson, Norma N ^a   Deja, Stanislaw ^a   Fu, Xiaorong ^a   Burgess, Shawn C ^a   Li, Cai ^b   Chakravarthy, Manu ^b   Previs, Steve ^b   Milstein, Stuart ^c   Fitzgerald, Kevin ^c   Kelley, David E ^b   Horton, Jay D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Structural Chemistry Department   (United States)

^c ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

acetyl CoA carboxylase; hepatic steatosis; hypertriglyceridemia; inhibitors; lipogenesis; malonyl CoA; SREBPs

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE INHIBITOR; ESSENTIAL FATTY ACID; KETONE; MALONYL COENZYME A; MK 4074; POLYUNSATURATED FATTY ACID; SMALL INTERFERING RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; ACACA PROTEIN, HUMAN; ACACB PROTEIN, HUMAN; ACACB PROTEIN, MOUSE; ACC1 PROTEIN, MOUSE; ENZYME INHIBITOR; SREBF1 PROTEIN, HUMAN; SREBF1 PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FATTY LIVER; HUMAN; HUMAN EXPERIMENT; HYPERTRIGLYCERIDEMIA; LIPOGENESIS; LIVER CELL; MALE; MOUSE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; ENZYMOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SECRETION (PROCESS);

ACETYL-COA CARBOXYLASE; ANIMALS; ENZYME INHIBITORS; FATTY LIVER; HEPATOCYTES; HUMANS; LIPOPROTEINS, VLDL; MICE; MICE, KNOCKOUT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES;

EID: 85025820702     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2017.08.011     Document Type: Erratum

References (60)

1. Aarsland, A., Chinkes, D., Wolfe, R.R., Hepatic and whole-body fat synthesis in humans during carbohydrate overfeeding. Am. J. Clin. Nutr. 65 (1997), 1774–1782.
2. Abu-Elheiga, L., Brinkley, W.R., Zhong, L., Chirala, S.S., Woldegiorgis, G., Wakil, S.J., The subcellular localization of acetyl-CoA carboxylase 2. Proc. Natl. Acad. Sci. USA 97 (2000), 1444–1449.
3. Abu-Elheiga, L., Matzuk, M.M., Abo-Hashema, K.A.H., Wakil, S.J., Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291 (2001), 2613–2616.
4. Abu-Elheiga, L., Oh, W., Kordari, P., Wakil, S.J., Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. Proc. Natl. Acad. Sci. USA 100 (2003), 10207–10212.
5. Abu-Elheiga, L., Matzuk, M.M., Kordari, P., Oh, W., Shaikenov, T., Gu, Z., Wakil, S.J., Mutant mice lacking acetyl-CoA carboxylase 1 are embryonically lethal. Proc. Natl. Acad. Sci. USA 102 (2005), 12011–12016.
6. Araújo, S., Soares E Silva, A., Gomes, F., Ribeiro, E., Oliveira, W., Oliveira, A., Lima, I., Lima Mdo, C., Pitta, I., Peixoto, C., Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD). Eur. J. Pharmacol. 788 (2016), 306–314.
7. Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L.J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y., DeFronzo, R.A., Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52 (2003), 1364–1370.
8. Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355 (2006), 2297–2307.
9. Bell, L.N., Wang, J., Muralidharan, S., Chalasani, S., Fullenkamp, A.M., Wilson, L.A., Sanyal, A.J., Kowdley, K.V., Neuschwander-Tetri, B.A., Brunt, E.M., et al., Nonalcoholic Steatohepatitis Clinical Research Network. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 56 (2012), 1311–1318.
10. Browning, J.D., Horton, J.D., Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114 (2004), 147–152.
11. Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., Grundy, S.M., Hobbs, H.H., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
12. Chakravarthy, M.V., Pan, Z., Zhu, Y., Tordjman, K., Schneider, J.G., Coleman, T., Turk, J., Semenkovich, C.F., “New” hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 1 (2005), 309–322.
13. Chakravarthy, M.V., Lodhi, I.J., Yin, L., Malapaka, R.R., Xu, H.E., Turk, J., Semenkovich, C.F., Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 138 (2009), 476–488.
14. Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., Charlton, M., Sanyal, A.J. American Gastroenterological Association American Association for the Study of Liver Diseases, American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
15. Choi, C.S., Savage, D.B., Abu-Elheiga, L., Liu, Z.X., Kim, S., Kulkarni, A., Distefano, A., Hwang, Y.J., Reznick, R.M., Codella, R., et al. Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc. Natl. Acad. Sci. USA 104 (2007), 16480–16485.
16. Cohen, J.C., Horton, J.D., Hobbs, H.H., Human fatty liver disease: old questions and new insights. Science 332 (2011), 1519–1523.
17. Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a Randomized Trial. Ann. Intern. Med. 165 (2016), 305–315.
18. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005), 1343–1351.
19. Engelking, L.J., Kuriyama, H., Hammer, R.E., Horton, J.D., Brown, M.S., Goldstein, J.L., Liang, G., Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J. Clin. Invest. 113 (2004), 1168–1175.
20. Fabbrini, E., Mohammed, B.S., Magkos, F., Korenblat, K.M., Patterson, B.W., Klein, S., Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134 (2008), 424–431.
21. Frank-Kamenetsky, M., Grefhorst, A., Anderson, N.N., Racie, T.S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. USA 105 (2008), 11915–11920.
22. Gonzalez-Baró, M.R., Lewin, T.M., Coleman, R.A., Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action. Am. J. Physiol. Gastrointest. Liver Physiol. 292 (2007), G1195–G1199.
23. Grundy, S.M., Brewer, H.B. Jr., Cleeman, J.I., Smith, S.C. Jr., Lenfant, C. American Heart Association, National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004), 433–438.
24. Harada, N., Oda, Z., Hara, Y., Fujinami, K., Okawa, M., Ohbuchi, K., Yonemoto, M., Ikeda, Y., Ohwaki, K., Aragane, K., et al. Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice. Mol. Cell. Biol. 27 (2007), 1881–1888.
25. Harriman, G., Greenwood, J., Bhat, S., Huang, X., Wang, R., Paul, D., Tong, L., Saha, A.K., Westlin, W.F., Kapeller, R., Harwood, H.J. Jr., Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc. Natl. Acad. Sci. USA 113 (2016), E1796–E1805.
26. He, S., McPhaul, C., Li, J.Z., Garuti, R., Kinch, L., Grishin, N.V., Cohen, J.C., Hobbs, H.H., A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285 (2010), 6706–6715.
27. Hellerstein, M.K., De novo lipogenesis in humans: metabolic and regulatory aspects. Eur. J. Clin. Nutr. 53:Suppl 1 (1999), S53–S65.
28. Hellerstein, M.K., Neese, R.A., Mass isotopomer distribution analysis: a technique for measuring biosynthesis and turnover of polymers. Am. J. Physiol. 263 (1992), E988–E1001.
29. Hellerstein, M.K., Schwarz, J.M., Neese, R.A., Regulation of hepatic de novo lipogenesis in humans. Annu. Rev. Nutr. 16 (1996), 523–557.
30. Horton, J.D., Shimano, H., Hamilton, R.L., Brown, M.S., Goldstein, J.L., Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J. Clin. Invest. 103 (1999), 1067–1076.
31. Horton, J.D., Goldstein, J.L., Brown, M.S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 109 (2002), 1125–1131.
32. Huang, Y., He, S., Li, J.Z., Seo, Y.K., Osborne, T.F., Cohen, J.C., Hobbs, H.H., A feed-forward loop amplifies nutritional regulation of PNPLA3. Proc. Natl. Acad. Sci. USA 107 (2010), 7892–7897.
33. Hudgins, L.C., Hellerstein, M.K., Seidman, C.E., Neese, R.A., Tremaroli, J.D., Hirsch, J., Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. J. Lipid Res. 41 (2000), 595–604.
34. Khan, M.A., St Peter, J.V., Xue, J.L., A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25 (2002), 708–711.
35. Lambert, J.E., Ramos-Roman, M.A., Browning, J.D., Parks, E.J., Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146 (2014), 726–735.
36. Li, J.Z., Huang, Y., Karaman, R., Ivanova, P.T., Brown, H.A., Roddy, T., Castro-Perez, J., Cohen, J.C., Hobbs, H.H., Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J. Clin. Invest. 122 (2012), 4130–4144.
37. Liang, K.-Y., Zeger, S.L., Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhyā: The Indian Journal of Statistics, Series B 62 (2000), 134–148.
38. Liang, G., Yang, J., Horton, J.D., Hammer, R.E., Goldstein, J.L., Brown, M.S., Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J. Biol. Chem. 277 (2002), 9520–9528.
39. Mao, J., DeMayo, F.J., Li, H., Abu-Elheiga, L., Gu, Z., Shaikenov, T.E., Kordari, P., Chirala, S.S., Heird, W.C., Wakil, S.J., Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis. Proc. Natl. Acad. Sci. USA 103 (2006), 8552–8557.
40. Mashhood, A., Railkar, R., Yokoo, T., Levin, Y., Clark, L., Fox-Bosetti, S., Middleton, M.S., Riek, J., Kauh, E., Dardzinski, B.J., et al. Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. J. Magn. Reson. Imaging 37 (2013), 1359–1370.
41. Matsuda, M., Korn, B.S., Hammer, R.E., Moon, Y.A., Komuro, R., Horton, J.D., Goldstein, J.L., Brown, M.S., Shimomura, I., SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev. 15 (2001), 1206–1216.
42. Minkler, P.E., Kerner, J., Kasumov, T., Parland, W., Hoppel, C.L., Quantification of malonyl-coenzyme A in tissue specimens by high-performance liquid chromatography/mass spectrometry. Anal. Biochem. 352 (2006), 24–32.
43. Moon, Y.-A., Horton, J.D., Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J. Biol. Chem. 278 (2003), 7335–7343.
44. Moon, Y.A., Hammer, R.E., Horton, J.D., Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. J. Lipid Res. 50 (2009), 412–423.
45. Moon, Y.A., Liang, G., Xie, X., Frank-Kamenetsky, M., Fitzgerald, K., Koteliansky, V., Brown, M.S., Goldstein, J.L., Horton, J.D., The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 15 (2012), 240–246.
46. Musso, G., Gambino, R., Cassader, M., Pagano, G., A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52 (2010), 79–104.
47. Musso, G., Cassader, M., Paschetta, E., Gambino, R., Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern. Med. 177 (2017), 633–640.
48. Olson, D.P., Pulinilkunnil, T., Cline, G.W., Shulman, G.I., Lowell, B.B., Gene knockout of Acc2 has little effect on body weight, fat mass, or food intake. Proc. Natl. Acad. Sci. USA 107 (2010), 7598–7603.
49. Promrat, K., Lutchman, G., Uwaifo, G.I., Freedman, R.J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004), 188–196.
50. Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., Boerwinkle, E., Cohen, J.C., Hobbs, H.H., Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40 (2008), 1461–1465.
51. Rong, S., Cortés, V.A., Rashid, S., Anderson, N.N., McDonald, J.G., Liang, G., Moon, Y.-A., Hammer, R.E., Horton, J.D., Expression of SREBP-1c requires SREBP-2-mediated generation of a sterol ligand for LXR in livers of mice. Elife, 6, 2017, e25015.
52. Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M., Neuschwander-Tetri, B.A., Lavine, J.E., Tonascia, J., Unalp, A., et al., NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362 (2010), 1675–1685.
53. Shimano, H., Horton, J.D., Hammer, R.E., Shimomura, I., Brown, M.S., Goldstein, J.L., Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J. Clin. Invest. 98 (1996), 1575–1584.
54. Shimano, H., Horton, J.D., Shimomura, I., Hammer, R.E., Brown, M.S., Goldstein, J.L., Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J. Clin. Invest. 99 (1997), 846–854.
55. Shimomura, I., Bashmakov, Y., Horton, J.D., Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J. Biol. Chem. 274 (1999), 30028–30032.
56. Shimomura, I., Bashmakov, Y., Ikemoto, S., Horton, J.D., Brown, M.S., Goldstein, J.L., Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. Proc. Natl. Acad. Sci. USA 96 (1999), 13656–13661.
57. Smagris, E., BasuRay, S., Li, J., Huang, Y., Lai, K.M., Gromada, J., Cohen, J.C., Hobbs, H.H., Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61 (2015), 108–118.
58. Thampy, K.G., Wakil, S.J., Regulation of acetyl-coenzyme A carboxylase. I. Purification and properties of two forms of acetyl-coenzyme A carboxylase from rat liver. J. Biol. Chem. 263 (1988), 6447–6453.
59. Thampy, K.G., Wakil, S.J., Regulation of acetyl-coenzyme A carboxylase. II. Effect of fasting and refeeding on the activity, phosphate content, and aggregation state of the enzyme. J. Biol. Chem. 263 (1988), 6454–6458.
60. Wolfe, R.R., Metabolic interactions between glucose and fatty acids in humans. Am. J. Clin. Nutr. 67:3 Suppl (1998), 519S–526S.